Immunotherapy combo may let some rectal cancer patients skip surgery

NCT ID NCT07561060

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen May 04, 2026 · Last updated May 16, 2026 · Updated 3 times

Summary

This study is for people with low rectal cancer that can be removed by surgery. Participants receive chemotherapy plus an immunotherapy drug (tislelizumab) before any surgery. If the tumor completely disappears after this treatment, they may avoid surgery and just be watched closely. If not, they will have standard surgery. The goal is to see if this approach can safely allow more people to keep their rectum.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Zhongshan Hospital, Shanghai
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RECTAL CANCER